Drug Profile

Lisdexamfetamine - Humanis Saglik Anonim Sirketi

Latest Information Update: 29 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Humanis Saglik Anonim Sirketi
Class Amides; Amphetamines; Antipsychotics; Behavioural disorder therapies; Drug withdrawal therapies; Neuropsychotherapeutics; Sleep disorder therapies; Small molecules
Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Attention-deficit hyperactivity disorder

Most Recent Events

17 Jul 2025 Humanis Saglik Anonim Sirketi completes a phase I trial in Attention-deficit hyperactivity disorder in India (PO) (NCT07098585)
26 May 2025 Phase-I clinical trials in Attention-deficit hyperactivity disorder in India (PO) (NCT07098585)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com